Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 43 of 43 matching drugs for DDR1 — including drugs targeting any of its 179 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib DDR1 Direct 2
gemcitabine, oxaliplatin, imatinib DDR1 Direct 1
imatinib, irinotecan, carboplatin DDR1 Direct 1
nilotinib DDR1 Direct yes 0
nilotinib hydrochloride monohydrate DDR1 Direct yes 0
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab DDR2 SSL via DDR2 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) DDR2 SSL via DDR2 4
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ERBB4 SSL via ERBB4 3
afatinib ERBB4 SSL via ERBB4 yes 3
mrtx849, pembrolizumab, cetuximab, afatinib ERBB4 SSL via ERBB4 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ERBB4 SSL via ERBB4 2
regorafenib DDR2 SSL via DDR2 yes 2
regorafenib, laboratory biomarker analysis DDR2 SSL via DDR2 2
afatinib, biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging ERBB4 SSL via ERBB4 1
afatinib, dasatinib, palbociclib, everolimus, olaparib ERBB4 SSL via ERBB4 1
afatinib, docetaxel, radiation therapy ERBB4 SSL via ERBB4 1
afatinib, gefitinib ERBB4 SSL via ERBB4 1
afatinib, irinotecan ERBB4 SSL via ERBB4 1
bosutinib CAMK2G SSL via CAMK2G 1
disulfiram, copper, alkylating agents GAPDH SSL via GAPDH 1
disulfiram, copper, alkylating agents SRSF1 SSL via SRSF1 1
gemcitabine, oxaliplatin, imatinib DDR2 SSL via DDR2 1
imatinib, irinotecan, carboplatin DDR2 SSL via DDR2 1
motixafortide, cemiplimab, gemcitabine, nab paclitaxel CXCR4 SSL via CXCR4 1
palbociclib, afatinib ERBB4 SSL via ERBB4 1
pantoprazole, omeprazole DDAH1 SSL via DDAH1 1
plerixafor CXCR4 SSL via CXCR4 yes 1
plerixafor, temozolomide, whole-brain radiotherapy (wbrt), radiation therapy CXCR4 SSL via CXCR4 1
radiation therapy, temozolomide, plerixafor, laboratory biomarker analysis, pharmacological study CXCR4 SSL via CXCR4 1
regorafenib, lomustine DDR2 SSL via DDR2 1
regorafenib, nivolumab, capeox, folfox regimen DDR2 SSL via DDR2 1
regorafenib, nivolumab, docetaxel, paclitaxel, irinotecan, trifluridine/tipracil DDR2 SSL via DDR2 1
regorafenib, temozolomide DDR2 SSL via DDR2 1
temozolomide, lomustine, regorafenib, radiation, paxalisib, val-083, vt1021, troriluzole, adi-peg 20 DDR2 SSL via DDR2 1
afatinib dimaleate ERBB4 SSL via ERBB4 yes 0
dacomitinib ERBB4 SSL via ERBB4 yes 0
fingolimod S1PR2 SSL via S1PR2 yes 0
fingolimod hydrochloride S1PR2 SSL via S1PR2 yes 0
neratinib ERBB4 SSL via ERBB4 yes 0
neratinib maleate ERBB4 SSL via ERBB4 yes 0
pentoxifylline PDE6H SSL via PDE6H yes 0
phenindione GGCX SSL via GGCX yes 0
vandetanib ERBB4 SSL via ERBB4 yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.